Werd Al-Najim
University College Dublin
H-index: 11
Europe-Ireland
Top articles of Werd Al-Najim
Factors that determine patients considering medication for the disease of obesity: an IMI2 SOPHIA study
2024/1/2
Werd Al-Najim
H-Index: 7
Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 …
Trials
2024/2/16
Werd Al-Najim
H-Index: 7
Carel W Le Roux
H-Index: 46
Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group …
The Lancet Regional Health–Europe
2024/2/9
Long‐term weight outcomes in patients treated with liraglutide 3.0 mg in real‐world clinical practice
Clinical Obesity
2024/2
Stratification of obesity phenotypes to optimize future therapy (SOPHIA)
2023/10/3
Obesity Treatments to Improve Type 1 Diabetes. The OTID trial Protocol for obesity treatments to improve Type 1 Diabetes. The OTID trial
2023/7/25
Werd Al-Najim
H-Index: 7
Carel W Le Roux
H-Index: 46
Food preferences after bariatric surgery: a review update
2023/3
Werd Al-Najim
H-Index: 7
Carel W Le Roux
H-Index: 46
Does bypass of the proximal small intestine impact food intake, preference, and taste function in humans? An experimental medicine study using the duodenal-jejunal bypass liner
Nutrients
2022/5/20
Duodenal-jejunal bypass liner for the management of type 2 diabetes mellitus and obesity: a multicenter randomized controlled trial
2022/3/1
The impact once-weekly semaglutide 2.4 mg will have on clinical practice: A focus on the STEP trials
2022/5/26
Werd Al-Najim
H-Index: 7
Carel W Le Roux
H-Index: 46
A Comparison of total food intake at a personalised buffet in people with obesity, before and 24 Months after roux-en-Y-gastric bypass surgery
Nutrients
2021/10/29
Dietary Choline Deprivation Exacerbates Cardiomyopathy in Streptozotocin-Induced Diabetic Adult Rats
Diabetology
2021/10/9
Ahmed Al-Humadi
H-Index: 2
Iordanis Mourouzis
H-Index: 19
Werd Al-Najim
H-Index: 7
Charis Liapi
H-Index: 12
Obesity and responsibility: Is it time to rethink agency?
2021/8
The effect of a duodenal-jejunal bypass liner on lipid profile and blood concentrations of long chain polyunsaturated fatty acids
Clinical nutrition
2021/4/1
Liraglutide Does Not Adversely Impact Fat‐Free Mass Loss
Obesity
2021/3
O33 Duodenal-jejunal bypass liner therapy (Endobarrier®) causes reductions in plasma trimethylamine-N-oxide in obese patients with diabetes
2021/1/1
P247 Safety profile of the duodenal-jejunal bypass liner (endobarrier): a multicentre randomised control trial
Gut
2021
Sa1961 ONE YEAR OF DUODENAL-JEJUNAL BYPASS LINER THERAPY (ENDOBARRIER®) LEADS TO SIGNIFICANT CHANGES IN LIVER BIOCHEMISTRY ASSOCIATED WITH NON-ALCOHOLIC FATTY LIVER DISEASE
Gastrointestinal Endoscopy
2020/6/1
The effect of a duodenal-jejunal bypass liner device (Endobarrier (R)) on insulin sensitivity
2020/3/1
One year of duodenal-jejunal bypass liner therapy (Endobarrier (R)) leads to perturbations in the metabolic profile of urine, plasma and stool of obese diabetic patients.
2020/3/1
